Geneos Wealth Management Inc. reduced its position in Northrop Grumman Corporation by 61.6% during the third quarter, selling 1,511 shares to end the period with 943 shares. At the end of that quarter, the remaining stake was valued at $575,000, reflecting Geneos’s strategic decision to sharply curtail its exposure to the aerospace and defense contractor.

Several other asset managers adjusted their holdings in the reporting period. Parvin Asset Management initiated a new position valued at approximately $25,000, while Twin Peaks Wealth Advisors added $31,000 worth of shares. NewSquare Capital increased its stake by 75%, acquiring 27 additional shares for a total investment of $31,000. AlphaQuest LLC boosted its stake by 29.2% to 93 shares, worth $46,000, and City Holding Co. more than doubled its position, adding 58 shares to reach a $50,000 holding. Taken together, institutional investors now account for 83.4% of the company’s outstanding shares.

During the recent quarter, insiders divested 10,097 shares valued at $6.1 million. Director Mark A. Welsh III sold 97 shares at an average price of $564.08, raising $54,716 and reducing his holding by 2.22% to 4,281 shares. CEO Kathy J. Warden sold 7,000 shares at $600 each, totaling $4.2 million and cutting her position by 3.47% to 194,602 shares. Insider ownership now represents 0.23% of total shares outstanding.

In the quarter ended September 30, Northrop Grumman reported $7.67 earnings per share, beating consensus by $1.24, on revenue of $10.42 billion, up 4.3% year-over-year but slightly below analyst forecasts. The company’s return on equity was 25.49% with a net margin of 9.82%. Management set full-year 2025 EPS guidance at a range of 25.650 to 26.050 and analysts forecast 28.05 EPS for the fiscal year. The board also declared a quarterly dividend of $2.31 per share, translating to a $9.24 annualized payout and a 33.24% payout ratio, payable to shareholders of record as of December 1.